Longbow Capital

MessageBird B.V. is a cloud communications platform that provides software solutions for customer communication, including voice services, SMS, email, and two-factor authentication. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in major cities such as San Francisco, London, and Singapore. MessageBird aims to simplify customer communication by offering a comprehensive suite of APIs that enable enterprises to connect reliably with their global customers. With its own telecommunications carrier infrastructure, MessageBird serves over 15,000 businesses, ensuring fast and dependable communication through SMS, voice, and chat services. The company has garnered significant attention and investment, including a notable $60 million Series A funding round in 2017, underscoring its position as a leading player in the European software industry.

Galatea Technologies operates a SaaS platform designed to optimize logistics processes in industries with complex, dynamic decision-making needs. Its initial application, Waste Coordinator, focuses on the oilfield waste sector. This platform automates transportation workflows, enabling users to enhance operational efficiency, financial performance, and environmental sustainability by optimizing disposal decisions and digitizing waste management processes.

MessageBird B.V. is a cloud communications platform that provides software solutions for customer communication, including voice services, SMS, email, and two-factor authentication. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in major cities such as San Francisco, London, and Singapore. MessageBird aims to simplify customer communication by offering a comprehensive suite of APIs that enable enterprises to connect reliably with their global customers. With its own telecommunications carrier infrastructure, MessageBird serves over 15,000 businesses, ensuring fast and dependable communication through SMS, voice, and chat services. The company has garnered significant attention and investment, including a notable $60 million Series A funding round in 2017, underscoring its position as a leading player in the European software industry.

Ambicare Health Ltd specializes in the development of innovative wearable light sources for medical and consumer healthcare applications. The company offers a range of products, including Ambulight PDT, a light-emitting sticking plaster designed for the treatment of non-melanoma skin cancer, providing a non-surgical alternative through photodynamic therapy. Additionally, Ambicare Health features the Lustre Pure Light product line, which includes devices that deliver blue light therapy aimed at combating spots and acne. These clinically proven products are designed for convenience and are available through various distributors and online platforms. Founded in 2004 and based in Livingston, United Kingdom, the company was previously known as Lumicure Ltd before rebranding in 2009.

Sky Medical Technology specializes in bioelectronic medicine, developing wearable devices that enhance blood circulation. Its flagship product, OnPulse™, is a neuromodulation therapy clinically proven to prevent and treat various vascular conditions such as life-threatening blood clots, post-surgical swelling, non-healing wounds, and muscle recovery for athletes.

Founded in 2001, Domainex Ltd. is a UK-based biotechnology company specializing in contract research and manufacturing services for drug discovery. It offers a range of services including medicinal chemistry, computational chemistry, protein expression, assay development, and DMPK analysis. The company also focuses on developing treatments for inflammatory diseases like rheumatoid arthritis.

Sky Medical Technology specializes in bioelectronic medicine, developing wearable devices that enhance blood circulation. Its flagship product, OnPulse™, is a neuromodulation therapy clinically proven to prevent and treat various vascular conditions such as life-threatening blood clots, post-surgical swelling, non-healing wounds, and muscle recovery for athletes.

Calon Cardio-Technology Ltd is a medical device company based in Swansea, United Kingdom, focused on developing innovative solutions for chronic heart failure. The company specializes in implantable micro blood pumps designed to enhance cardiac function and alleviate the symptoms associated with heart failure. Its flagship product, the MiniVAD, is a miniature device implanted into the left ventricle of the heart to improve blood supply and potentially slow the progression of heart failure. In addition to the MiniVAD, Calon offers the MicroVAD, aimed at earlier intervention for patients experiencing advancing heart failure, and the CathVAD, a catheter-delivered micro-pump specifically designed for treating acute heart failure. Established in 2007, Calon Cardio-Technology is dedicated to advancing cardiac care through minimally invasive surgical options.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

Ambicare Health Ltd specializes in the development of innovative wearable light sources for medical and consumer healthcare applications. The company offers a range of products, including Ambulight PDT, a light-emitting sticking plaster designed for the treatment of non-melanoma skin cancer, providing a non-surgical alternative through photodynamic therapy. Additionally, Ambicare Health features the Lustre Pure Light product line, which includes devices that deliver blue light therapy aimed at combating spots and acne. These clinically proven products are designed for convenience and are available through various distributors and online platforms. Founded in 2004 and based in Livingston, United Kingdom, the company was previously known as Lumicure Ltd before rebranding in 2009.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Sky Medical Technology specializes in bioelectronic medicine, developing wearable devices that enhance blood circulation. Its flagship product, OnPulse™, is a neuromodulation therapy clinically proven to prevent and treat various vascular conditions such as life-threatening blood clots, post-surgical swelling, non-healing wounds, and muscle recovery for athletes.

Destiny Pharma is a clinical-stage biotechnology company based in Brighton, United Kingdom, specializing in the discovery and development of innovative antimicrobial products aimed at treating infectious diseases. The company's lead candidates include XF-73 Nasal, currently in Phase II clinical trials for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, in Phase I trials for treating skin infections caused by antibiotic-resistant bacteria. Destiny Pharma also develops other compounds, such as XF-70 for treating ventilator-associated pneumonia and DPD-207 for eye infections, as well as additional XF drugs targeting antibiotic-resistant biofilm infections. The company has established several collaboration agreements with various academic institutions and organizations, enhancing its research capabilities and broadening its therapeutic focus. Founded in 1996, Destiny Pharma is committed to addressing the growing global healthcare challenge posed by drug-resistant bacteria.

Biotronics3D, Ltd., established in 2004 and based in London, UK, specializes in developing and marketing innovative software applications for the diagnostic imaging industry. The company's flagship product, 3Dnet Suite, is a multi-purpose medical imaging application suite designed to facilitate clinical data analysis and enhance diagnostic capabilities. It includes modules such as 3Dnet Colon for virtual colonoscopy and 3Dnet Vessel for identifying vascular anomalies. Biotronics3D's software technologies aim to improve healthcare by extracting and transforming diagnostic data into usable information at the point-of-care. The company is certified to the EN ISO 13485:2003 standard and its products have received FDA 510K clearance and CE marking.

Cyden Limited, established in 2002 and headquartered in Swansea, UK, is a medical device company specialising in the design, manufacture, and distribution of intense pulsed light (IPL) technology devices. Its product portfolio includes the i200+, i300, and i400, catering to various salon and home environments. Cyden's IPL devices are used for hair removal and reduction, as well as skin treatments such as rejuvenation, thread vein removal, and pigmented lesion reduction. The company serves customers worldwide through a network of distributors across Africa, America, Asia, Europe, and the Middle East.

Founded in 2001, Domainex Ltd. is a UK-based biotechnology company specializing in contract research and manufacturing services for drug discovery. It offers a range of services including medicinal chemistry, computational chemistry, protein expression, assay development, and DMPK analysis. The company also focuses on developing treatments for inflammatory diseases like rheumatoid arthritis.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.